Skip to main content

nimbus-therapeutics-logo

Nimbus Therapeutics will have $43 million to progress clinical trials of its non-alcoholic liver disease drug after the company successfully completed a financing round.

The Series B investment was led by Pfizer Venture Investments and Lightstone Ventures. Previous investors, including Atlas Venture, SR One, Lilly Ventures and Bill Gates, also participated.

{iframe}http://www.bizjournals.com/boston/blog/health-care/2015/03/nimbus-therapeutics-begins-liver-disease-trials.html{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.